Volume 132, Issue 4



July 26, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Review series- hematologic malignancies in adolescents and young adults.
See the articles in this review series.

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Although mantle cell lymphoma is an aggressive lymphoma, the non-nodal subtype is more indolent. However, distinguishing classical and non-nodal subtypes can be challenging. Clot et al demonstrate that a 16-gene signature reliably differentiates the 2 subtypes and helps to predict outcome.

Hypoxia downregulates protein S expression
Pilli and colleagues demonstrate that hypoxia downregulates protein S expression through HIF1, potentially explaining the link between hypoxia and increased thrombosis.

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
In the 5-year final report of the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial, Cortes et al report durable and deep responses to ponatinib with acceptable toxicity in heavily pretreated patients with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL).

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL
Testi et al present results from the International Consortium for Childhood APL, demonstrating outstanding outcomes using reduced dose anthracycline and risk-adapted consolidation therapy.

Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency
Heeney and colleagues present an algorithm that allows distinction between chronic iron deficiency and iron-resistant iron deficiency caused by TMPRSS6 mutations. This was accomplished by normalizing hepcidin levels to serum transferrin saturation or serum iron levels.

Introduction to a review series on adolescent and young adult malignant hematology
Treating hematologic malignancies in adolescent and young adults (AYA) has unique biologic, therapeutic, and social challenges. This Review Series focuses on these unique features in discussing the approach to the AYA population in treating leukemias and lymphomas, with a final review focused on the general psychosocial challenges of this population.

The articles in this review series, "Adolescent and Young Adult Malignant Hematology":


View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.